OTC: HLUBF - H. Lundbeck A/S

半年間の収益性: -27.38%
配当利回り: +16.83%
セクタ: Healthcare

プロモーションスケジュール H. Lundbeck A/S


会社について H. Lundbeck A/S

H. Lundbeck A/S, a biopharmaceutical company, engages in the research, development, production, and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company's principal products include Abilify Maintena for schizophrenia; Brintellix/Trintellix to treat depression; Northera for the treatment of symptomatic neurogenic orthostatic hypotension; Vyepti for migraine prevention; and Rexulti/Rxulti to treat depression/schizophrenia.

さらに詳しく
It also provides Azilect for treating Parkinson's disease; Cipralex/Lexapro for depression; Ebixa to treat Alzheimer's disease; Onfi for Lennox-Gastaut syndrome; Sabril for treating epilepsy; and Xenazine for chorea associated with Huntington's disease, as well as other products. The company sells its products primarily to distributors of pharmaceuticals, pharmacies, and hospitals. It has a partnership collaboration with Otsuka Pharmaceuticals Co., Ltd.; and collaboration with FeetMe focusing on the use of sensor shoe soles. H. Lundbeck A/S also has a collaboration with Alloy Therapeutics, Inc. for the discovery of novel biologics therapies. The company was founded in 1915 and is headquartered in Valby, Denmark.

Industry Pharmaceuticals
Sector Health Care
Валюта usd
Валюта отчета usd
Див.доход ао 16.83
Дивиденд ао 0.7
Сайт https://www.lundbeck.com
Цена ао 4.43
1日あたりの価格変動: 0% (4.43)
週ごとの価格変動: 0% (4.43)
月ごとの料金変更: 0% (4.43)
3ヶ月間の価格変動: -15.09% (5.2175)
半年間の価格変動: -27.38% (6.1)
年間の価格変動: +3.87% (4.265)
3年間の価格推移: 0% (4.43)
5年間の価格推移: 0% (4.43)
10年間の価格推移: 0% (4.43)
年初からの価格変動: -15.62% (5.25)

過小評価

名前 意味 学年
P/S 1.39 9
P/BV 0.1858 10
P/E 12.08 8
EV/EBITDA 4.3 10
合計: 9.38

効率

名前 意味 学年
ROA, % 0.9065 1
ROE, % 1.54 1
合計: 2.5

配当金

名前 意味 学年
Div yield, % 16.83 10
DSI 1 10
合計: 8.41

義務

名前 意味 学年
Debt/EBITDA 5.05 0
合計: 6

成長の衝動

名前 意味 学年
収益性 Revenue, % -83.42 0
収益性 Ebitda, % -81.03 0
収益性 EPS, % -97.51 0
合計: 1.6



スーパーバイザー 役職 支払い 生年
Mr. Joerg Hornstein CFO & Executive VP of Corporate Functions 1.23M 1977 (48 年)
Mr. Lars Bang Executive Vice President of Product Development & Supply 1.14M 1962 (63 年)
Dr. Per Johan Luthman Executive Vice President of Research & Development 1.27M 1959 (66 年)
Mr. Charl van Zyl President & CEO 5.34M 1967 (58 年)
Dr. Tarek Samad Ph.D. Senior VP & Head of Research N/A
Mr. Palle Holm Olesen Chief Specialist & VP of Investor Relations N/A
Mr. Ole Chrintz Senior Vice President of International Markets N/A 1958 (67 年)
Dr. Rupert Sandbrink M.D., Ph.D. Senior VP & Head of Clinical Development N/A 1964 (61 年)
Ms. Tine Ostergaard Hansen Senior Vice President of Corporate Communications & Public Affairs N/A 1975 (50 年)
Ms. Dianne Holto Executive Vice President of People & Culture 1973 (52 年)

住所: Denmark, Valby, Ottiliavej 9 - Googleマップで開く, Yandexマップを開く
Webサイト: https://www.lundbeck.com